|Depomed Acquires US Rights to CAMBIA Migraine Medicine|
|By Staff and Wire Reports|
|Tuesday, 17 December 2013 21:27|
Depomed, Inc. (NASDAQ: DEPO) announced that it has acquired the United States rights to CAMBIA® (diclofenac potassium for oral solution) from Nautilus Neurosciences for $48.7 million. In addition, Depomed may pay Nautilus up to an additional $5 million based on the achievement of certain annual net sales milestones. CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) indicated for acute treatment of migraine attacks with or without aura in adults 18 years of age or older.
CAMBIA is a powdered formulation of diclofenac potassium that is dissolved in liquid. It has a rapid onset and has demonstrated in clinical studies relief of the pain and associated symptoms of migraine, including nausea, sensitivity to light and sensitivity to sound. It was launched in 2010.
Important Safety Information: CAMBIA is a non-steroidal anti-inflammatory drug (NSAID). NSAIDs may increase your chance of a heart attack or stroke that can lead to death. This chance is higher with longer use of NSAID medicines and in people who have heart disease. CAMBIA should never be used right before or after certain heart surgeries.
NSAID medicines can also cause stomach and intestine problems, such as ulcers and bleeding, which can happen without warning and may cause death. This risk increases with use of steroids (corticosteroids), blood thinners (anticoagulants), smoking, alcohol use, older age, and for those in poor health.
ActiveCare, Inc. (OTCQB: ACAR), a leader in diabetes management and wellness services, announced today it completed the sale of $3,120,000 in 8% Original Issue Discount Senior Convertible Series F Preferred shares in a private placement. Under the terms of the securities purchase agreement with Hillair Capital Investments L.P. and other investors, ActiveCare has authorized the sale of up to a total of $6,000,000 of its Series F Preferred shares.
Athersys, Inc. (Nasdaq:ATHX) announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has issued a positive opinion (EMA/OD/146/13) for the Company's allogeneic, multipotent adult progenitor cell, or MultiStem® therapy, for the prevention of graft-versus-host disease (GvHD).
Biodel Inc. (Nasdaq:BIOD) today announced a long-term supply agreement with BD (Becton, Dickinson and Company), a leading global medical technology company, for worldwide exclusive rights to the novel and proprietary BD Uniject SCF™ Disposable Auto-Disable Injection System for the delivery of liquid glucagon to treat severe hypoglycemia. Financial terms of the agreement have not been disclosed.
Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:NBI).
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that it has priced a firm commitment underwritten public offering of 12,000 units of Series D convertible preferred stock and warrants at a price to the public of $1,000 per unit for gross proceeds of $12 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company.
Neptune Technologies & Bioressources Inc. (Nasdaq:NEPT) (TSX:NTB), Acasti Pharma Inc. (Nasdaq:ACST) (TSX-V:APO), a Neptune subsidiary, and Aker BioMarine AS, Aker BioMarine Antarctic AS and Aker BioMarine Antarctic USA jointly announce a settlement and license agreement that will result in the dismissal of all AKBM respondents from the on-going ITC investigation brought by Neptune and Acasti, as well as the dismissal of all current lawsuits brought by Neptune against AKBM and companies in its value chain.
Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) today announced that pursuant to the previously announced exclusive out-license and strategic partnership agreement between Pluristem Ltd. and South Korea-based CHA Bio&Diostech (Kosdaq:CHA), the details of which were announced on June 26, 2013.
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations and combinations of existing drugs, today announced that the first patients have been dosed in the Phase III ERADICATE Hp clinical study in the U.S.
RedChip Companies, Inc., an international small-cap research, investor relations, and media company, today announced that "The RedChip Money Report: Small Stocks Big Money" television program featured an interview with Sorrento Therapeutics, Inc.'s (Nasdaq:SRNE) CEO Henry Ji on Bloomberg Europe, Sunday, December 15.
Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) and its development and commercialization partner Takeda Pharmaceuticals today announced the initiation of a global pivotal Phase 3 clinical program of lubiprostone in pediatric functional constipation.
Vical Incorporated (Nasdaq:VICL) today announced the initiation of its Phase 1/2 trial of the company's Vaxfectin™-formulated therapeutic vaccine for herpes simplex virus type 2 (HSV-2), a cause of genital herpes, in approximately 156 subjects.